
Health Care Association of NJ Annual Convention & Expo


October 24, 2018



Shereef Elnahal, M.D., M.B.A. Commissioner New Jersey Department of Health

Eradicating the Opioid Epidemic





Eradicating the Opioid Epidemic

\$100M FY19 Budget

- Prevention, Treatment and Recovery: MAT, Peer Coaches
- Social Risk Factors: housing & employment training
- Infrastructure and Data: EHRs, workforce development

\$30.6M Federal Funds

- \$21.5M to expand access to MAT, Narcan, and alternatives to opioids
- \$5.6M integrated substance use /mental health services at Community Health Centers
- \$3.4M to assist counties in expanding treatment, preventing infants born addicted and increasing alternatives to opioids



Intervening Before Neonatal Abstinence Syndrome



Since 2008, cases of NAS in NJ have doubled to 685 babies diagnosed in 2016

- Most common substances used by NJ's pregnant women:
 - Heroin (59.8%)
 - Other opiates (9.7%)
 - Marijuana (13.5%);
 - and Alcohol (9.3%)



Treating "Behind the Wall"

- About 65% of 2.3M U.S. inmates meet medical criteria for substance abuse addiction
 - But only about 11% actually receive treatment
- Risk of death from overdose in 2 weeks following release is 129 times general population

DMHAS Pilot Program

- John Brooks Recovery
 Center Mobile Van/Atlantic
 County Jail
- Began in August 2017
 - Served 345 people to date



Integrated Health

DOH supports an overall system of integrated health care in NJ


- Creating a single license for integrated care
- Modernizing/streamlining its licensing process for all types of healthcare facilities
- Addressing barriers to integrated health






Eliminating the Opioid Epidemic in NJ: A Comprehensive, Public Health Approach

Journey Map of Opioid Crisis



Prescription Monitoring Data




Expanding access to medicinal marijuana





- 34,000 patients
 - Increase of 17,000 since new administration began, including 14,100 with new medical conditions
- 800 physicians
- 1,345 caregivers
- 6 Alternative Treatment Centers (ATC)
- 146 Applications rec'd 8/31 for up to 6 new ATCs



Patient Demographics







Forms of Therapy

Current forms of medicinal marijuana in NJ

All Patients:

- Oral primarily lozenges that dissolve in the mouth
- Topical—oils, ointments, and other formulations that are meant to be absorbed through the skin
- Flower the "buds" that can be smoked, vaporized, or baked

Adults:

- Oil oils that contain extracted THC and CBD that can be vaporized
 - Pre-filled vape cartridges authorized mid-September 2018

Minors:

Edibles – tablets, capsules, drops or syrups that are ingested



Requirements and Eligibility

Qualifying Conditions

Debilitating:

- Amyotrophic lateral sclerosis
- Multiple sclerosis
- Terminal cancer
- Muscular dystrophy
- Inflammatory bowel disease (IBD), including Crohn's disease
- Forminal illness, if the physician has determined a prognosis of less than 12 months of life.

Resistance, or intolerance, to conventional therapy:

- Seizure disorder, including epilepsy
- Intractable skeletal muscular spasticity
- Glaucoma
- Post-Traumatic Stress Disorder (PTSD)

Severe or chronic pain, severe nausea or vomiting, cachexia or wasting syndrome resulting from the condition or treatment of:

- Positive status for human immunodeficiency virus (HIV)
- Acquired immune deficiency syndrome (AIDS)
- Cancer



New Qualifying Medical Conditions

Added in March 2018:

- Chronic pain related to musculoskeletal disorders
- **Migraine**
- Anxiety
- Chronic pain of visceral origin
- Tourette's Syndrome



Opioid Use Disorder

Table 1. Diagnostic Criteria for an Opioid-Use Disorder.*

Use of an opioid in increased amounts or longer than intended

Persistent wish or unsuccessful effort to cut down or control opioid use

Excessive time spent to obtain, use, or recover from opioid use

Strong desire or urge to use an opioid

Interference of opioid use with important obligations

Continued opioid use despite resulting interpersonal problems, social problems (e.g., interference with work), or both

Elimination or reduction of important activities because of opioid use

Use of an opioid in physically hazardous situations (e.g., while driving)

Continued opioid use despite resulting physical problems, psychological problems, or both

Need for increased doses of an opioid for effects, diminished effect per dose, or both $\dot{\uparrow}$

Withdrawal when dose of an opioid is decreased, use of drug to relieve withdrawal, or both $\dot{\uparrow}$

- Petitioned on 9/7/2016
- Reviewed and recommended by Review Panel in 2017 for patients w OUD w chronic pain
- Accepted on 3/22/2018, but only for patients where opioid use disorder resulted from the use of opioids for chronic pain
- DOH recommending considering adding condition for SUD when using MAT
 - MMP Review Panel will consider when it reconvenes



^{*} If two or three items cluster together in the same 12 months, the disorder is mild; if four or five items cluster, the disorder is moderate; and if six or more items cluster, the disorder is severe. Criteria are from the *Diagnostic and Statistical Manual of Mental Disorders*, fifth edition.⁸

[†] If the opioid is taken only as prescribed, this item does not count toward a diagnosis of an opioid-use disorder.

Evidence: Opioids and Opioid Abuse

Association of Medical and Adult-Use Marijuana Laws With Opioid Prescribing for Medicaid Enrollees

Wen et al., JAMA Intern Med. 2018;178(5):673-679. doi:10.1001/jamainternmed.2018.1007

Design:

 Population-based, cross-sectional, longitudinal analysis of Medicaid prescription claims data for 2011 to 2016

Results:

- State implementation of medical marijuana laws was associated with a 5.88% lower rate of opioid prescribing (95% CI-11.55% to approximately -0.21%)
- The implementation of adult-use marijuana laws in states with existing medical marijuana laws was associated with a 6.38% lower rate of opioid prescribing (95% CI-12.20% to approximately -0.56%)

Conclusion:

The potential of marijuana liberalization to reduce the use and consequences of prescription opioids among Medicaid enrollees deserves consideration during the policy discussions about marijuana reform and the opioid epidemic.

Evidence: Opioids and Opioid Abuse

Association Between US State Medical Cannabis Laws and Opioid Prescribing in the Medicare Part D Population

Bradford et al., JAMA Intern Med. 2018;178(5):667-672. doi:10.1001/jamainternmed.2018.0266

Design:

• Longitudinal analysis of the daily doses of opioids filled in Medicare Part D for all opioids as a group and for categories of opioids by state and state-level Medical Cannabis Law (MCL) from 2010 through 2015.

Results:

- Analysis results found that patients filled fewer daily doses of any opioid in states with an MCL
 - States with active dispensaries saw 3.742 million fewer daily doses filled

Conclusion:

• Medical cannabis laws are associated with significant reductions in opioid prescribing in the Medicare Part D population. This finding was particularly strong in states that permit dispensaries, and for reductions in hydrocodone and morphine prescriptions.

Medicinal Marijuana as Treatment

- HIV/AIDS improved mood, sleep, reduced neuropathic pain (Haney, et al. *J Acquir Immune Defic Syndr*. 2007; Abrams, et al. *Neurology* 2007)
- Arthritis reduced inflammation
 (Blake, et al. *Rheumatology*. 2006; Croxford, et al. *J Neuroimmunol*. 2005)
- Cancer preventing nausea, pain, slowing cell growth (Galve-Roperh, et al. Nature Medicine 2000; Manuel Nature Reviews Cancer. 2003)



- Crohn's/IBD reduced symptoms of pain, diarrhea (Lahat, et al. Digestion. 2012)
- Epilepsy reduce Seizures (Davinksy et. Al. NYU Langone Medical Center. 2015)
- MS reduced muscles spasms, pain, stiffness (Zajicek, et al. J Neurol Neurosurg Psychiatry. 2012)



Short term side effects

<u>Marijuana</u>	Benzodiazepines	<u>Opioids</u>	<u>Steroids</u>
Sedation	Sedation	Sedation	Fluid retention
Impaired short-term memory	Dizziness	Dizziness	High blood pressure
Impaired motor coordination	Weakness	Nausea	Problems with mood, memory, behavior
Altered judgement	Unsteadiness	Vomiting	Weight gain
Paranoia	Loss of orientation	Constipation	Insomnia
	Confusion	Respiratory depression	Blurred vision



Effects of long term use

<u>Marijuana</u>	Benzodiazepines	<u>Opioids</u>	<u>Steroids</u>
Associated with greater risk of developing psychoses Increased risk of social	Cognitive impairment	Constipation Sleep-disordered	Cataracts
anxiety disorder	Adverse effects on sleep	breathing	High blood sugar
Potential lasting cognitive deficits	Increased risk of fall and fracture	Increased risk of overdose (2 in 1000 risk of death)	Increased risk of infections
Increased risk of bronchitis (smoking only)	Increased risk of depression, anxiety, other mental health conditions	Depression	Thinning bones
	Risk of severe withdrawal after only 1 month of regular use	Increased risk of fall and fracture	Suppressed adrenal gland hormone production
		87% increase in all cause mortality	Thin skin, bruising, slower wound healing



Addiction, Withdrawal and Overdose

	<u>Marijuana</u>	<u>Prescription</u> <u>Benzodiazepines</u>	Prescription Opioids
Use disorder prevalence	9%	As many as 23% of long term users	8-12% develop addiction
Severity of withdrawal	Minor	Major	Major
Worst Symptoms	Dysphoria, Disturbed Sleep, Decreased Appetite	Severe Depression, Catatonia, Convulsions, Death	Abdominal Cramps, Pain, Anxiety, High Blood Pressure, Severe Cravings, Depression
Overdose Deaths (2015)	0	8,791	22,598



Program Improvements:

- Expanding Access:
 - 146 Applications rec'd 8/31 for up to 6 new ATCs
- Physician Friendly:
 - Doctors no longer required to be listed on public website (optional)
- ATCs Can Post Prices so patients can comparison shop
- Provisional Caregiver Status (temp cards)
- New Patient processing time down to 2 weeks
- Expanding Product:
 - Oil oils that contain extracted THC and CBD that can be vaporized
 - Authorized pre-filled vape cartridges authorized mid-September 2018
- Mobile Access:
 - Patients, caregivers & physicians can access register, upload documents & make payments on Smart phones & tablets (April 2018)
- Revised Rules:
 - Reviewing Comments; finalized soon



AL Considerations

- State law/regulations do not prohibit medicinal marijuana administration to residents of Assisted Living facilities
- Facilities should consult with counsel on policies, procedures, and guidance to ensure compliance with the medical marijuana rules and Assisted Living regulations
- When DOH survey staff conduct surveys/investigate complaints will assess:
 - compliance with smoking regulations
 - the facility policies
 - and safety of residents



Advanced Standing

- Pilot began in 2012
- Special designation when quality standards achieved
- 3-year extension via Memorandum of Agreement
- Development of rules to support continuation



For more information visit:

www.nj.gov/health

Follow us:

Twitter: @ShereefElnahal; @NJDeptofhealth

www.facebook.com/NJDeptofHealth

Instagram @njdeptofhealth

Snapchat @njdoh

Sign up for the Health Matters newsletter:

www.state.nj.us/health/newsletter

